Multiple studies have shown that combining a VEGF inhibitor with an EGFR-TKI is significantly more effective than EGFR-TKI monotherapy in patients with advanced EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.